Search results
Earnings call: Veracyte sees robust growth driven by diagnostics platform
Investing.com· 10 hours agoThe company's revenue reached $96.8 million, marking a 17% increase from the same period last year,...
Prostate cancer: Supplement, keto diet may boost immunotherapy
Medical News Today· 6 days agoAbout 13% of cisgender men around the world will receive a prostate cancer diagnosis in their...
O.J. Simpson died from prostate cancer, not COVID-19 vaccine | Fact check
USA Today· 5 days agoAn April 13 Instagram post (direct link, archive link) shows an image of Dr. Anthony Fauci above an...
...Potential of Profound Medical’s TULSA Procedure Becoming a Mainstream Treatment Modality Across...
Digital Journal· 2 days ago“The TACT 5-year clinical trial data, along with multiple real-world reports on the safety, efficacy and durability of TULSA from U...
Guy Carbonneau helps shed light on men’s health | Montréal Canadiens
NHL· 5 days agoRecently, the three-time Stanley Cup champion teamed up with Pros Talk Prostate, a men’s health...
Earnings call: FibroGen reports Q1 2024 results, optimistic about pipeline By Investing.com
Investing.com· 1 day agoThe company highlighted the upcoming top line data from Phase 3 studies for pamrevlumab in...
King Charles III’s openness about cancer has helped him connect with people in year after coronation
The Bryan-College Station Eagle· 2 hours agoKing Charles III’s decision to be open about his cancer diagnosis has helped the new monarch connect...
Baby Boomers' 14 Least Favorite Drug Brands: Ranked
247wallst.com· 2 hours agoBaby boomers are currently one of the oldest demographics. For this reason, they’re also some of the most familiar with medications. But with so many...
Phase 2 data for ERLEADA® (apalutamide) plus androgen deprivation therapy following radical...
St. Louis Post-Dispatch· 5 days agoJohnson & Johnson announced today results from the open-label, single-arm Phase 2 Apa-RP study evaluating adjuvant treatment with ERLEADA® (apalutamide) and androgen deprivation therapy (ADT ...
Citi cuts ORIC Pharmaceuticals stock price target post 1Q24 pipeline update By Investing.com
Investing.com· 1 day agoORIC Pharmaceuticals is set to begin combination trials for its drug candidate, ORIC-944, a PRC2...